Montrusco Bolton Investments 13F: Cuts DHR Stake by $34M
The investment firm cut its Danaher holdings by 14.3%, now holding 912,150 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Montrusco Bolton Investments sold 152,432 shares from its stake in Danaher Corporation ($DHR), a 14.32% decrease, according to a 13F filing with the SEC dated October 13, 2026. It reported 912,150 shares worth $202.09 million at the end of the quarter.
Since the filing, $DHR is up 2.8% to date (from the $222.84 close on Oct 13, 2026).
Find the original: Montrusco Bolton Investments 13F filings on SEC EDGAR
DHR
Danaher Corporation
Key Points
- Montrusco Bolton Investments reduced its stake in Danaher Corporation by 14.3%, selling 152,432 shares to hold 912,150 shares valued at $202.1 million.
- Danaher has a market cap of $151.7 billion, a P/E ratio of 38.5, and a 52-week range between $160.93 and $242.80.
- The company pays an annual dividend of $1.60 per share, yielding 0.76% with a payout ratio of 25.67%.
Get $DHR trade alerts by text
We text you when insiders, Congress or big funds trade $DHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Montrusco Bolton Investments has trimmed its holdings in Danaher Corporation (NYSE: DHR) by 14.3%, according to its latest filing with the SEC. The firm sold 152,432 shares, bringing its total down to 912,150 shares, with a reported value of about $202.1 million. This move was disclosed in a 13F filing, which reveals holdings as of the reporting period and may not represent current positions.
Montrusco Bolton Investments vs. the S&P 500
Hypothetical returns from Montrusco Bolton Investments's disclosed trades, not real profit or advice. How we model this.
What Changed in Montrusco Bolton Investments' Danaher Position
Montrusco Bolton Investments reduced its position in Danaher Corporation by selling 152,432 shares. This cut represents a 14.3% decrease in their holdings, leaving them with 912,150 shares. The value of this stake is approximately $202.1 million.
Danaher Corporation Stock Up 2.1%
Shares of Danaher Corporation have traded within a 52-week range of $160.93 to $242.80. The company, which operates in the healthcare sector, has a market capitalization of $151.7 billion. Danaher's P/E ratio stands at 38.5, with a forward P/E of 23.2, indicating investor expectations of future earnings growth. The stock's beta is 0.808, suggesting it is less volatile than the broader market. With a current ratio of 1.65 and a quick ratio of 1.15, Danaher maintains a stable liquidity position. Additionally, its debt-to-equity ratio is 52.97.
Recent Earnings
In its most recent earnings report, Danaher Corporation posted revenue of $25.1 billion, reflecting a growth rate of 5.5%. The company's net margin was 15.95%, and it achieved a return on equity of 7.61%. Earnings per share were reported at $5.61. The next earnings announcement is scheduled for October 20, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher Corporation offers its shareholders an annual dividend of $1.60 per share, yielding 0.76%. The dividend payout ratio is 25.67%, indicating a balanced approach to returning capital to shareholders while reinvesting in the business. The ex-dividend date was not specified.
About Danaher Corporation
Danaher Corporation, headquartered in Washington, DC, designs and manufactures a wide range of professional, medical, research, and industrial products. It operates through three main segments: Biotechnology, Life Sciences, and Diagnostics. The company provides technologies and services that advance the development and manufacture of therapeutics, diagnostic tools, and healthcare solutions. Led by CEO Rainer M. Blair, Danaher employs around 58,000 people and serves markets in the United States, China, and internationally.
Bottom Line
Montrusco Bolton Investments' recent reduction in its Danaher stake highlights the firm's strategic portfolio adjustments. Investors often track such moves to gauge confidence levels and market sentiment. It's important to remember that these 13F filings are backward-looking and may not reflect current positions. Danaher's strong market presence and consistent dividend make it a company to watch in the healthcare sector.
Related Filing Alerts
Source: Montrusco Bolton Investments's 13F filing on $DHR (Oct 13, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Montrusco Bolton Investments 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts